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Abstract
Acting as the chief mediators of vesicular fusion, soluble N-ethylmaleimide-sensitive
factor attachment protein receptors (SNAREs) play a role in many intracellular trafficking events
by moving opposing membranes into close proximity. One such event takes place in the process
of autophagy. A key SNARE involved in autophagy is Synaptosome Associated Protein 29
(SNAP-29), which acts on the autophagosome membrane to promote autophagosome and
lysosome fusion. Kaposi’s Sarcoma Herpesvirus (KSHV) proteins ORF33 and ORF38 were
demonstrated to interact with SNAP-29. The exact mechanism of this interaction is yet to be
elucidated but it is hypothesized that these interactions allow KSHV to modulate mast cell
autophagy to sustain viral replication. Mast cell degranulation was also demonstrated to be
increased upon exposure to KSHV, which might increase tumor progression and viral replication
in Kaposi’s Sarcoma. To fully characterize the interaction between SNAP29 and KSHV proteins,
a recombinant pMBP-parallel-1 expression vector containing human SNAP-29 cDNA was
generated. PCR was utilized to amplify SNAP-29 cDNA and insert restriction enzyme sites.
Restriction digestion and subsequent ligation were carried out to generate the recombinant
pMBP-parallel-1-SNAP-29 construct. This construct was confirmed by sequencing and then
used to transform Rosetta 2 (DE3) E. coli cells. These cells were then induced by IPTG to
express the SNAP-29 protein. SNAP-29 expression was confirmed by the increased intensity of
the 71.5 Kda band on an SDS-PAGE gel. Future site-directed mutagenesis of the generated
SNAP-29 construct will allow for the identification of the functional domains within SNAP-29
that interact with the ORF33/38 complex through lipid-mixing assays. It is anticipated that these
studies may reveal potential therapeutic targets for Kaposi’s Sarcoma.
Keywords: SNARE, mast cell, Herpesvirus, Kaposi, autophagy, membranes
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Chapter 1: Introduction
1.1: Role of Mast Cells as Inflammatory Mediators
Mast cells (MCs) are a specialized class of white blood cells that carry out an
important role in the human body by responding to pathogens and mediating the release
of a variety of compounds upon antigen exposure (Urb & Sheppard, 2012). Mast cells are
known to release proinflammatory modulators as well as proteases that cleave
inflammatory cytokines (Piliponsky, et al., 2012; Waern, et al., 2012). The release of
these contents allows mast cells to maintain the homeostatic balance of both
proinflammatory and anti-inflammatory mediators (Xu & Sugita, 2018).
Localized primarily in human tissues such as mucosal linings and the connective
tissue lining blood vessels (Gilfillan & Beaven, 2011; Moon, et al., 2010), mast cells are
activated to release active compounds stored in endocytic vesicles, called granules. This
activation is initiated by many ligand-receptor interactions including immunoglobulin E
(IgE) and pathogen-associated molecular pattern recognition receptor stimulation
(Shelburne & Abraham, 2011), inducing signaling cascades to eventually release a
variety of mediator molecules (Xu & Sugita, 2018). The actions of these mediators are
associated with activating both native and adaptive immune responses. These actions
allow mast cells and the granular contents they release to serve as integral regulators in
ensuring the proper functionality of the immune system (Gilfillan & Beaven, 2011). Mast
cell mediators broadly fall under two main classes: preformed mediators (including
histamine and β-hexosaminidase) and newly synthesized mediators (including cytokines
and chemokines). These mediators are released through either regulated or constitutive
exocytosis mechanisms (Xu & Sugita, 2018).
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The release of contents stored in MC granules is further described as anaphylactic
degranulation (AND) or piecemeal degranulation (PMD). Anaphylactic degranulation
refers to the homotypical fusion of granules with one another and the heterotypical fusion
of granules with the cytoplasmic membrane to result in complete release of vesicle
contents. Piecemeal degranulation refers to the transport of granule contents into smaller
vesicles before heterotypical fusion (Xu & Sugita, 2018). The variation in mechanisms
used to release granule contents adds complexity to the exocytic pathways utilized by
MCs and complicates the current understanding of the modes by which these pathways
are regulated.
The dysregulation of MC degranulation plays a key role in the pathobiology of a
variety of human diseases including cancer, autoimmunity, cardiovascular disease, and
allergic inflammation (Xu & Sugita, 2018). The pathobiology of allergic inflammation is
directly propagated by the binding of IgE to IgE receptors found on the MC plasma
membrane to initiate overactive degranulation. These degranulation events are
characterized by a massive release of proinflammatory mediators, including histamine, to
result in the production of the acute phase allergic reaction in hypersensitivity responses,
such as asthma (Lei, Gregory, Nilsson, & Adner, 2013). This process first involves the
production of secreted IgE by plasma cells under the direction of Th2 released cytokines
during the type 1 hypersensitivity reaction. This cytokine release is followed by
subsequent binding of IgE to the Fc receptor specific to IgE, FcεRI, found on the cell
membrane of mast cells. This process is known as IgE sensitization. Next, an antigen or
allergen will bind to IgE and initiate receptor aggregation and subsequent cross-linking of
IgE molecules (Gilfillan & Beaven, 2011). The formation of this cross-linkage initiates
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the influx of Ca2+ through inositol triphosphate intracellular signaling to initiate a cascade
within the MC (Kraft, & Kinet, 2007). This multistep signaling cascade ends in the
eventual release of MC granular contents, including histamine and interleukins, which
perform a variety of actions within the body, including promoting inflammation (Gilfillan
& Beaven, 2011) (Fig.1). The prevalence of MC degranulation in hypersensitivity-related
diseases including asthma has prompted the detailed characterization of the specific
downstream protein interaction cascade that gives rise to MC degranulation.

Figure 1: Schematic of IgE Dependent Mast Cell Degranulation
IgE sensitization is the first step of the IgE dependent MC degranulation pathway and is
dependent on the binding of IgE produced by plasma cells to FcεRI situated on the MC
membrane facing the extracellular space. Next, the binding of an antigen or allergen
stimulates the cross-linking of IgE, which stimulates a signaling cascade within the cell.
This results in degranulation, which leads to the release of a variety of mediator
molecules. Retrieved from Arora, P., & Ansari, S. H. (2019). Role of Various Mediators
in Inflammation of Asthmatic Airways. In Asthma-Biological Evidences. IntechOpen.
1.2: Role of SNARE Proteins in Mast Cell Degranulation
In mast cell IgE dependent degranulation, SNARE proteins (Soluble NSF Factor
Receptors) are activated in a calcium dependent fashion and catalyze the fusion of vesicle
and plasma membranes to result in MC degranulation (Nishida, et al., 2005). These
proteins are a conserved group of eukaryotic membrane bound proteins that are found on
3

both vesicular and plasma membranes associated with the fusion of membranes in a
variety of biological processes. Opposing SNARE partners interact to give rise to a fourhelical bundle known as the trans-SNARE complex. The formation of the trans-SNARE
complex typically involves the interaction between one R-SNARE and either two or three
Q-SNAREs. The distinction between R and Q refers to whether an arginine (R) or
glutamine (Q) side chain is contributed to the helical bundle. Additionally, Q-SNAREs
are further classified as either Qa-SNAREs which contribute one helix to the four-helical
bundle or Qbc-SNAREs which contribute two helices to the four-helical bundle.
Contrastingly, R-SNAREs always contribute one helix to the four-helical bundle
(Fasshauer, Sutton, Brunger, & Jahn, 1998; Kloepper, Kienle, & Fasshauer, 2007).
Membrane fusion events along the secretory pathways and the endocytic pathways
require the interaction of three Q-SNAREs on one membrane and one R-SNARE on the
other (Fasshauer, et al., 1998).
Although they are the principal drivers of membrane fusion, SNAREs rely on
other protein partners for the successive steps of docking, priming, and lipid fusion to
occur. Docking is carried out by a protein called exocyst and involves the trafficking of
vesicles to the target membrane (Toonen, et al., 2006). Next, Qa- and Qbc-SNAREs
interact to form a resting cis-SNARE complex on the plasma membrane. Munc13, Nethylmaleimide-sensitive factor (NSF), and other factors interact with the SNARE
machinery and partially assemble the Q-SNAREs and R-SNAREs into the trans-SNARE
complex, priming the vesicle and target membrane (Toonen, et al., 2006). Lastly, IgE
stimulation results in the influx of calcium ions into the mast cell. Synaptotagmin is
activated upon calcium binding to assist the trans-SNARE complex in bringing the
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opposing membranes into close proximity, permitting fusion of the membranes and
resulting in exocytosis.
The specific Q-SNAREs contributing to mast cell degranulation have been
identified as SNAP-23 and Syntaxin (STX) 2, 3, 4, and 6. The specific R-SNAREs
contributing to mast cell degranulation have been identified as Vesicle associated
membrane protein (VAMP) 2, 3, 4, 7, and 8 (Lorentz, Baumann, Vitte, & Blank, 2012).
The interaction between SNARE proteins along with the interaction of SNARE accessory
proteins, including Munc18, Munc13, and Rab GTPases, gives rise to mast cell
degranulation upon mast cell activation (Lorentz, et al., 2012) (Fig. 2).

Figure 2: Schematic of SNARE Mediated Membrane Fusion VAMP8, the R-SNARE,
is brought into close proximity to the cis-SNARE complex of Qa-SNARE STX4 and
Qbc-SNARE SNAP-23 during the translocation step. The trans-SNARE complex
between the Q-SNAREs and R-SNARE is then formed in the priming step leading to
fusion of the two membranes which results in exocytosis. Adapted from Lorentz, A.,
Baumann, A., Vitte, J., & Blank, U. (2012). The SNARE machinery in mast cell
secretion. Frontiers in immunology, 3, 143.

1.3: SNAP-29 Participates in Autophagolysosome Formation
Although not implicated in the well-described mechanism of mast cell
degranulation, SNAP-29 is a Qbc-SNARE found in mast cells that has been identified as
a key component in autophagosome-lysosome fusion in Drosophila (Takáts, et al., 2018).
5

Within this model, SNAP-29 and STX-17 have been demonstrated to form a transSNARE complex with R-SNARE VAMP-8 to promote the fusion of the autophagosome
and lysosome vesicles (Takáts, et al., 2018).
Autophagosome-lysosome fusion is an event that takes place during the process
of autophagy. Autophagy is a mechanism that is utilized by eukaryotic cells to recycle
damaged or worn organelles and to liberate nutrients during a state of cellular stress
(Karanasios & Ktistakis, 2016). This process is also carried out by the cell to combat
intracellular pathogens by trafficking them to lysosomes for degradation (Levine, 2005).
As a result, many families of viruses have been shown to exploit the autophagosomelysosome fusion process to aid viral replication and maturation within host cells
(Richards & Jackson, 2012). For example, Picornavirus EV-D68 is a respiratory virus
that interacts with SNAP-29 to signal the autophagic pathway. This interaction also
promotes viral replication during the early stages of replication. The Qbc-SNARE is
subsequently cleaved during cellular exit to prevent autophagolysosome formation in
H1HeLa cells (Corona, Saulsbery, Velazquez, & Jackson, 2018). The EV-D68 C3 protein
was demonstrated to perform the proteolytic cleavage of SNAP-29 at Q161 to prevent the
fusion of the lysosome and autophagosome, thus favoring viral replication in late stages
of viral replication (Corona, et al., 2018).
1.4: Mast Cells Are Implicated in the Pathobiology of Kaposi’s Sarcoma
Mast cells have also been implicated in the pathogenesis of Herpesviruses
associated diseases including Kaposi’s Sarcoma (KS) (Ayers, et al., 2018; Aoki, et al.,
2013). Kaposi’s Sarcoma is described as a hemorrhagic condition of endothelial cells
(ECs) caused by the infection of Kaposi’s Sarcoma Herpesvirus (KSHV). The tumors
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that arise from KSHV infection are characterized by invading leukocytes as well as
proliferating spindle-shaped ECs, which accumulate (Ganem, 2006). However, these ECs
have been demonstrated to grow in culture without producing viral progeny, indicating
that infected ECs envelop latent virus and are not able to harbor infectious KSHV
(Grundhoff, & Ganem, 2004). In contrast, MCs have been observed to play a large role in
perpetuating KSHV, as these cells have been shown to support viral gene expression and
sustain an infectious viral load for long durations (Ayers, et al., 2018). Furthermore, in
addition to serving as a potential reservoir of KSHV, mast cells are known to increase
degranulation upon interaction with expressed viral proteins (Ayers, et al., 2018).
Harboring KSHV in MCs is thought to result in the long-term propagation of the active
viral infection in ECs (Ayers, et al., 2018). The increased activation of MCs and
subsequent abundant release of heparin and histamines is implicated in edema and
increased tumorigenesis and hemorrhaging of closely associated blood vessels (Ayers, et
al., 2018). These outcomes are consistent with the histologic features presented in KS and
the known effects of these mediators (Ayers, et al., 2018). Therefore, it is postulated that
the combination of MC activation along with the release of viral progeny from these
infected cells results in the progression of KS tumors (Fig. 3).
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Figure 3: Role of Mast Cells in Perpetuation of KS Mast cells were observed to
maintain a high viral titer throughout KSHV infection. These cells were also shown to be
activated under infection conditions to release mediators associated with tumor
progression. Adapted from Ayers, L. W., Barbachano-Guerrero, A., McAllister, S. C.,
Ritchie, J. A., Asiago-Reddy, E., Bartlett, L. C., ... & King, C. A. (2018). Mast cell
activation and KSHV infection in Kaposi sarcoma. Clinical Cancer Research, 24(20),
5085-5097
Recently, conserved Herpesviridae proteins ORF33 and ORF38 have been linked
to the replication and maturation process of KSHV (Wu, et al., 2016). Both of these
proteins were found to be expressed in the late lytic cycle and to be retained in mature
viruses as tegument proteins. The ORF38 protein was shown to colocalize with Golgi and
early endosome vesicles. Interaction between ORF38 and ORF33 was found to be crucial
for optimal production of progeny virions through the triggered expression of RTA, thus
inducing lytic gene expression (Wu, et al., 2016). The KS protein ORF33 was found to
localize on cytosolic vesicles once bound by ORF38. Importantly, these KSHV tegument
proteins have been demonstrated to carry out interactions with Qbc-SNARE protein
SNAP-29 (Xu, unpublished). However, the precise mechanism of these interactions has
yet to be examined. Determining the mechanism by which these interactions take place
may unveil therapeutic targets which can be exploited to prevent the perpetuation of KS
by mast cells. Targeting the protein domains involved in these interactions could
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effectively reduce the progression of KS tumors and allow for more efficacious treatment
when combined with classical therapeutic strategies.
1.5: Hypothesis
It has previously been shown that, once KSHV enters the MC, tegument proteins
ORF38 and ORF33 interact with SNAP-29. It is hypothesized here that ORF 33/38 may
act in a manner similar to EV-D68 protein C3 and cleave SNAP-29 between its two
SNARE binding motifs to prevent formation of the autophagolysosome. Furthermore, it
is thought that this mode of interaction with autophagolysosomal fusion machinery would
enable MCs to serve as reservoirs of viral progeny during KSHV infection.
In order to test this hypothesis, SNAP-29 was cloned into the E. coli expression
vector pMBP-parallel-1 and expressed in E. coli Rosetta 2 (DE3) cell lines. The
generation of this construct will allow future studies to be conducted to dissect
interactions between KSHV proteins and SNAP-29. In those studies, lipid fusion assays
will be carried out, which will employ the principles of mutational analysis to elucidate
which SNAP-29 domains interact with KSHV tegument proteins ORF33/38. Determining
the interaction of these participating domains may identify drug targets within SNAP-29,
which may be exploited to enhance autophagosome-lysosome fusion and promote MC
clearance of the virus.
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Chapter 2: Methods and Materials
2.1 Experimental Strategy
A classical cloning approach was utilized in order to produce the recombinant SNAP-29
construct and subsequently express the protein. Firstly, SNAP-29 cDNA was amplified
and restriction enzyme sites were inserted using a standardized protocol. Both pMBPparallel-1 and the amplified SNAP-29 cDNA were digested with BamHI and XbaI.
Ligation was then carried out and the construct was used to transform NovaBlue E. coli.
Next, plasmid DNA was isolated from these cells and subsequently analyzed by DNA
sequencing. The recombinant plasmid was then used to transform Rosetta 2 (DE3) E.
coli, which were then induced to express SNAP-29. Expression of the protein was
analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
2.2 cDNA and Vector Information
The human SNAP-29 cDNA was obtained from the pMRXIP GFP-SNAP-29 plasmid
from Noboru Mizushima (addgene plasmid #45923). The pMBP-parallel-1 vector was
obtained from the HXB_OC21 strain cultured in the C992 derivative of DH5 alpha E.
coli obtained from Kevin Collins of The Geisel School of Medicine at Dartmouth. A
vector map of pMBP-parallel-1 is detailed in Fig. 4.
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Figure 4: pMBP-parallel-1 Vector Map AmpR refers to the ampicillin resistance gene
and MBP refers to the maltose binding domain of the fusion protein product. The
nucleotide sequence for pMBP-parallel-1 was obtained from NCBI and mapped using
SnapGene.
2.3 Cloning Oligoprimer Design
To insert SNAP-29 into the pMBP-parallel-1 vector, cloning primers had to be designed.
First, the sequence of SNAP-29 was input into the online program NEBcutter 2.0 in order
to determine the restriction enzyme sites to include in the designed primers. The selection
of BamHI and XhoI was made on the basis that these two cut sites were found within the
multiple cloning site of the pMBP-parallel-1 vector but not within the sequence of
SNAP-29. BamHI was selected for the 5’ oligoprimer and XhoI was selected for the 3’
oligoprimer, as these cut sites lie on the 5’ and 3’ end of the pMBP-parallel-1 multiple
cloning site, respectively. The designed primers are detailed in Table 1. Capital letters
denote restriction enzyme sites. The HXO_E14 primer contains a restriction site for
BAM HI while HXO_E15 contains a restriction site for XhoI. An extra guanosine
11

nucleotide was included in primer HXO_E14 so that SNAP-29 would be in frame with
MBP and the TEV site upon ligation. These oligoprimers were custom made by Sigma
Aldrich.
Table 1: Designed Cloning Primers
Oligoprimer
Name

Nucleotide Sequence
5'atgGGATCCgatgtcagcttaccctaaaagcHXO_E14
3'
5'-ccgCTCGAGtcagagttgtcgaacttttcHXO_E15
3'
Capital letters denote restriction enzyme sites.

GC
Content

Tm

Directionality

48% 73°C Forward
52% 73°C Reverse

2.4 PCR
The SNAP-29 cDNA was amplified via polymerase chain reaction (PCR) using the
designed cloning primers and the pMRXIP GFP-SNAP-29 plasmid as the template. The
PCR mixture components were added to a PCR tube on ice and mixed by spinning. The
contents and volumes aliquoted into the PCR mixture are detailed in Table 2. A
micropipette was used to add sterile Millipore water, 10X Pfu Polymerase Buffer, 10 µM
Primer HXO_E14, 10 µM Primer HXO_E15, 10 µM dNTPs, Pfu DNA Polymerase, and
template SNAP-29. The PCR mixture was then subjected to the PCR program outlined in
Fig. 5. After the conclusion of the PCR program, the PCR product was stored at -20ºC.
Table 2: Components of PCR Mixture
Component
Volume
10X Pfu Polymerase Buffer
5μL
Tempelate SNAP29 (295.5ng/μL)
0.5μL
10μM FWD Primer (HXO_E14)
1μL
10μM RVS Primer (HXO_E15)
1μL
10μM dNTPs
1μL
Pfu DNA Polymerase (G Bioscience)
1μL
Sterile Millipore Water
40.5μL
12

Hold at 94°C for 5 minutes.

5 cycles

25 cycles

Figure 5: SNAP-29 PCR Program The SNAP-29 cDNA was amplified using a
standardized PCR protocol. The annealing temperature for the first five cycles was
lowered as to accommodate the difference in annealing temperatures between the two
oligoprimers.
2.5 PCR Product Purification
Following PCR, the amplified SNAP-29 cDNA containing a 5’ BamHI and a 3’ XbaI
restriction site was purified using the QIAquick PCR Purification Kit to remove DNA
polymerase, residual primers, and any salts from the polymerase buffer. A micropipette
was used to add 250 µL of Buffer PB and 50 µL of the PCR product mixture into a sterile
1.5 mL microfuge tube. This solution was mixed by spinning and transferred to a QIA
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spin column that was placed inside a collection tube. The sample was then centrifuged at
17,000 xg for one minute. The flow-through was discarded and the column was replaced
inside the collection tube. A micropipette was used to add 750 µL of Buffer PE to the
spin column to wash the sample. The sample was again centrifuged at 17,000 xg for one
minute. The flow-through was discarded and the column was again replaced inside the
collection tube. This was repeated twice more for a total of three centrifugations after
adding Buffer PE. The spin column was then placed into a sterile 1.5 mL microfuge tube.
A micropipette was used to add 30 µL of sterile Millipore water to the center of the spin
column membrane. The spin column was held at room temperature for one minute before
centrifugation at 17,000 xg to elute the purified DNA. The absorbance of the eluted DNA
was then measured by a Nanodrop spectrophotometer, using sterile Millipore water as the
blank. The spectrophotometer was used to determine the concentration of DNA in the
sample as well as purity denoted by absorbance values. A micropipette was used to load 1
µL of the eluted DNA into the spectrophotometer, which provided the concentration of
the sample in ng/µL and absorbance ratios as A260/230 and A260/280. The purified PCR
product was then stored at -20 ºC.
2.6 Restriction Digestion
To insert SNAP-29 into the pMBP-parallel-1 vector, both the cDNA and the vector were
digested by restriction enzymes BamHI and XbaI. The contents of the restriction digest
mixtures, which were prepared on ice, are detailed in Table 3. The reactions were then
mixed, placed in a water bath and incubated at 37 ºC for 3 h. The reactions were then
mixed by spinning and placed on a heat block to incubate at 65 ºC for 20 min to stop the
restriction digestion reaction. The SNAP-29 double digest was then stored at -20 ºC. A
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micropipette was then used to add 1 µL of 1,000 U/mL shrimp alkaline phosphatase
(rSAP) (supplied by NEB) to double digested pMBP-parallel-1 to dephosphorylate the 5’
end of the linearized vector. The rSAP reaction was then mixed and placed into a water
bath at 37 ºC for one hour. The rSAP reaction mixture was then mixed by spinning and
placed on a heat block to incubate at 65 ºC for 20 minutes to stop the reaction. Following
inactivation, the vector was then stored at -20 ºC.
Table 3: Components of Restriction Digestion Mixtures
SNAP 29 Double Digest
Component
PCR Purified SNAP29
10X NEB CutSmart Buffer
BamHI HF
XhoI
Sterile Millipore Water

Volume
27μL
5μL
1μL
1μL
16μL

pMBP-parallel-1 Double Digest
Component
pMBP-parallel-1
10X NEB CutSmart Buffer
BamHI HF
XhoI
Sterile Millipore Water

Volume
25μL
5μL
1μL
1μL
18μL

Total Volume:

50μL

Total Volume:

50μL

2.7 Gel Electrophoresis
To separate the digested fragments of interest, both the digested SNAP-29 insert and the
digested pMBP-parallel-1 vector were subjected to electrophoresis on an agarose gel. A
0.7% agarose gel was prepared by dissolving 350 mg of agarose in 50 mL of 0.5X TBE
buffer. The 0.5X TBE buffer was diluted tenfold from a 1 L 5X TBE (pH 8.3) stock
solution containing 54 g Tris base, 27.5 g boric acid, and 20 mL 0.5 M EDTA (pH 5)
dissolved in sterile Millipore water. The agarose and buffer were added to a 250 mL
Erlenmeyer flask and heated by microwaving for three 30 second intervals. The solution
was mixed in-between each interval until the solution became clear. The molten agarose
solution was then poured into a gel casting apparatus which contained a gel tray with a
comb inserted. The gel was kept at room temperature for 45 minutes to solidify. The
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solidified gel inside of the gel tray was then transferred into a gel electrophoresis tank
filled with 0.5X TBE buffer. The tank was then further filled with 0.5X TBE buffer until
the gel became completely submerged. Samples were then loaded into each well along
with 2 µL of 18X Gel Red and autoclaved Millipore water to equal 10 µL of each loaded
sample. The 10,000X Gel Red stock (Biotium) was diluted to 100X in Millipore water.
This 100X solution was then diluted with 6X purple loading dye (NEB) to make the 18X
Gel Red solution. The top was then placed onto the gel electrophoresis chamber and the
gel was electrophoresed at 80 V for 60 minutes at varying amplitude.
2.8 Gel Purification
Following gel electrophoresis, the desired bands were then purified. This procedure was
carried out using the QIAquick Gel Extraction Kit. A clean and sharp scalpel was used to
excise the desired bands (0.7 kb for SNAP-29 and 6.7 kb for pMBP-parallel-1). These
excised bands were then added to separate sterile microfuge tubes and placed on a
microscale to weigh the fragments. The fragment weights were then recorded. A
micropipette was then used to add three volumes of Buffer QG to one gel volume in the
microfuge tube. The two microfuge tubes were then incubated at 50 ºC inside of a heat
block. The microfuge tubes were vortexed every two minutes for the duration of 10
minutes until the gel fragments were dissolved. A micropipette was then used to add one
gel volume of isopropanol to each microfuge tube before mixing both tubes by spinning.
Two spin columns were then placed into two 2 mL tubes labeled SNAP-29 and pMBPparallel-1. A micropipette was used to transfer each sample into the appropriate spin
column. Next, a micropipette was used to add 750 µL of Buffer PE to each column. Both
columns were then centrifuged at 17,000 xg for one minute and the flow-through was
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discarded. The columns were centrifuged two additional times at 17,000 xg for one
minute to rid the samples of residual buffer. Each column was placed into a clean 1.5 mL
microcentrifuge tube labeled SNAP-29 and pMBP-parallel-1. A micropipette was used to
add 30 µL of sterile Millipore water to each column. Each column was centrifuged at
17,000 xg for one minute. Each eluted sample was loaded onto a NanoDrop
spectrophotometer to determine the absorbance values and concentration of each sample.
2.9 Ligation Reaction
Following gel purification, the purified SNAP-29 and pMBP-parallel products were
subjected to a ligation reaction to insert SNAP-29 into the vector. The components of the
ligation mixture were added via a micropipette into a sterile PCR tube on ice. A control
mixture was also included which lacked the SNAP-29 insert to assay vector selfreannealing. A micropipette was used to add sterile Millipore water, 10X T4 DNA Ligase
Buffer (NEB), 16.8 ng/µL pMBP-parallel-1, T4 DNA Ligase (NEB), and 27.4 ng/µL
SNAP-29. The components of each mixture are detailed in Table 4. Once these
components were added, both sample solutions were mixed by spinning. Both mixtures
were then incubated at 17 ºC in a thermocycler for 16 hours. The ligation products were
stored at -20 ºC.
Table 4: Components of Ligation Reactions
Ligation Reaction
Component
Sterile Millipore Water
10X T4 Ligase Buffer
16.8ng/μL pMBP-parallel-1
T4 DNA Ligase
27.4ng/μL SNAP29
Total Volume:

Volume
10.5μL
1.5μL
1.5μL
1μL
0.5μL
15μL

Vector Only Control
Component
Sterile Millipore Water
T4 Ligase Buffer
16.8ng/μL pMBP-parallel-1
T4 DNA Ligase
27.4ng/μL SNAP29
Total Volume:
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Volume
11μL
1.5μL
1.5μL
1μL
15μL

2.10 Preparation of LB Plates with Selective Antibiotics
Selective lytic broth (LB) plates were prepared to isolate transformed colonies.
Ampicillin at a concentration of 100 µg/mL was used to isolate transformed cells since
the pMBP-parallel-1 vector contains an ampicillin resistance gene.
Firstly, 6 g of Bacto agar was measured and placed into a sterilized 500 mL bottle. A
graduated cylinder was used to add 300 mL of freshly prepared LB media into the
500 mL bottle. This bottle was then labeled and autoclaved through a liquid 20 cycle. The
bottle of dissolved LB agar was allowed to cool at room temperature. Once the solution
had cooled, a micropipette was used to add 300 µL of 100 mg/mL ampicillin to the LB
agar to yield 300 mL of LB agar containing 100 µg/mL ampicillin. Approximately 20 mL
of this solution was poured into each petri dish over a Bunsen burner. These plates were
held at room temperature until they became solidified. The plates were labeled AMP 100
and stored at 4 ºC.
2.11 Transformation of NovaBlue Cells
Competent NovaBlue E. coli were transformed using the ligation mixture as well as the
vector only mixture to serve as a control. First, competent NovaBlue E. coli cells were
allowed to thaw on ice. These cells were mixed by pipetting up and down with a
micropipette. A micropipette was then used to mix 2.0 µL of each ligation mixture with
20 µL of competent cells in separate clean 1.5 mL microfuge tubes. The competent cells
were mixed together with the ligation mixtures by gently tapping the wall of the
microfuge tubes. The cells and ligation mixture were then kept on ice for 45 minutes.
Next, the cells were placed on a heat block set at 42 ºC for 30 seconds to heat shock the
cells. A micropipette was used to add 100 µL of SOC medium to each microfuge tube.
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The medium was added over a Bunsen burner to decrease the risk of contamination. The
entire volume of each microfuge tube was added to 100 µg/mL ampicillin LB agar plates.
Five autoclaved glass beads were then added to each plate. The plates were rotated
horizontally for 15 seconds to create a bacterial lawn. Next, the plates were placed in a
37 ºC incubator for 20 minutes. The plates were then flipped upside down and stored in
the 37 ºC incubator overnight.
2.12 Streaking Colonies
Transformed colonies were streaked onto new plates to ensure that pure colonies were
obtained. The 100 µg/mL ampicillin LB agar plate containing transformed colonies was
retrieved from the 37 ºC incubator. Four fresh 100 µg/mL ampicillin LB agar plates were
retrieved from 4 ºC storage and allowed to warm at room temperature. Next, an
individual colony was picked from the agar plate containing transformed colonies using a
wooden inoculation wand. This process was carried out over a Bunsen burner to decrease
the risk of contamination. This colony was streaked over one quarter of a fresh 100
µg/mL ampicillin LB agar plate. This wand was discarded, and a fresh wand was used to
streak the remaining three quarters of the plate. This process was carried out for the four
individual colonies. Each streaked plate was held at 37 ºC overnight in the incubator.
2.13 Overnight Culture Inoculation
The four streaked plates were retrieved from the 37 ºC incubator and placed at room
temperature. Over a Bunsen burner, 5 µL of 100 mg/mL ampicillin was added to four test
tubes, each containing 5 mL of LB medium to prepare 100 µg/mL ampicillin LB. A
single colony was picked from each streaked plate using a clean inoculation wand and

19

placed into a test tube containing 100 µg/mL ampicillin LB. These inoculated cultures
were placed in a 37 ºC rotating shaking incubator overnight.
2.14 Plasmid DNA Isolation
The overnight cultures were used to isolate the plasmid DNA using the QIA Miniprep kit.
The four overnight cultures were placed on ice and vortexed to resuspend cells at the
bottom of the test tube. A serological pipette was used to add 1.5 mL of each culture to a
microfuge tube. These tubes were centrifuged at 17,900 xg for one minute. The
supernatant was decanted before adding an additional 1.5 mL of the culture to the tube.
The samples were again centrifuged at 17,000 xg for one minute. The supernatant was,
again, decanted and the pellet was vortexed until all sediment was resuspended. A
micropipette was used to add 250 µL of buffer P1 as well as to add 250 µL of buffer P2
to each tube. The tubes were inverted ten times and the solution was noted to become
clear. A micropipette was used to add 350 µL of buffer N3 to each tube. The tubes were
again inverted ten times before centrifuging at 17,000 xg for 10 minutes at 4ºC. The
supernatant was removed from each tube and added to a QIA column which was placed
inside of a 1.5 mL microfuge tube. Each tube was centrifuged at 17,000 xg for one
minute. The flow through was discarded and a micropipette was used to add 500 µL of
buffer PB to each QIA column. Each column was again centrifuged at 17,000 xg for one
minute. The flow through was discarded and a micropipette was used to add 750 µL of
buffer PE to each QIA column. Each tube was centrifuged at 17,000 xg for one minute.
The flow through was then discarded and the columns were centrifuged twice more to
remove any residual buffer. Each column was transferred into a clean 1.5 mL microfuge
tube. A micropipette was used to add 50 µL of autoclaved Millipore water to each tube.
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The tubes were held at room temperature for one minute and then were centrifuged at
13,000 xg for one minute. Each isolated plasmid was loaded onto a NanoDrop
spectrophotometer so that the concentration and purity of the sample could be obtained.
The samples were then stored at -20 ºC.
2.15 Plasmid DNA Sequencing
To verify that the correct plasmid had been isolated, two plasmids isolated from separate
colonies were mailed to Eurofins Genomics for sequencing. The components that were
included in each tube were added on ice. A micropipette was used to add 5.9 µL of the
isolated plasmid DNA (Table 7), 4 µL of a 1.6 µM pMBP forward primer, and 2.1 µL of
autoclaved Millipore water. The sequencing primer details are included in Table 5.
Table 5: Sequencing Primer Information

2.16 Transformation of E. coli Rosetta 2 (DE3) Expression Cells
Once the plasmid of interest was verified by sequencing, Rosetta 2 (DE3) expression E.
coli cells (Novagen) were transformed with the plasmid. Two separate transformation
reactions were carried out. One transformation was carried out using SNAP-29 Isolate #1
while the other transformation was carried out using SNAP-29 Isolate #2. Firstly, the
cells were thawed on ice and mixed by gently flicking the container. A micropipette was
used to transfer 10 µL of competent cells to two sterile 1.5 mL microfuge tubes along
with 1 µL of plasmid DNA. The components were mixed by again gently flicking the
container. These cells were held on ice for 45 minutes before heat shocking the cells at
42 ºC for 45 seconds. The transformation mixtures were returned to ice for 20 minutes. A
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micropipette was then used to add 90 µL of LB medium to the transformation mixtures.
The mixtures were placed into an incubator and held at 37 ºC for one hour. Next, the
transformation mixtures were plated onto two LB agar plates containing 34 µg/mL
chloramphenicol and 100 µg/mL ampicillin. Five sterile glass beads were added to each
plate which was then rotated horizontally to spread the bacterial cells across the plate.
The plates were placed into an incubator and held at 37 ºC for 20 minutes before flipping
the plates and holding them at 37 ºC overnight.
2.17 Small-Scale IPTG Protein Induction
After transformation, a colony was streaked from each transformation plate. A single
colony was inoculated from each streak plate into separate tubes containing 5 mL of LB
medium with 34 µg/mL chloramphenicol and 100 µg/mL ampicillin. These tubes were
incubated at 37 ºC overnight in the rotating shaker. The optical density at 600 nm
wavelength (OD600) was measured 17 hours later. Next, a micropipette was used to add
800 µL of the overnight cultures into separate tubes containing 10 mL of fresh LB along
with 34 µg/mL chloramphenicol and 100 µg/mL ampicillin to reach OD600 = 0.08. These
cultures were mixed gently by pipetting and divided into two separate tubes labeled IPTG
(+) and IPTG (-). This was done for both overnight cultures meaning there was a total of
four tubes. All four of the tubes were held at 37 ºC in the rotating shaker for three hours,
until the cultures reached OD600 = 0.4. A micropipette was used to add 2.5 µL of 1M
Isopropyl β-d-1-thiogalactopyranoside (IPTG) to each IPTG (+) tube to reach 0.5 mM
IPTG. Each tube was then returned to the rotating shaker and held at 37 ºC for 4 hours.
Next, the OD600 was again obtained from each culture. One ODmL was then taken from
each culture and placed into a 1.5 mL microfuge tube. These 1 ODmL samples were spun
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in a microfuge for one minute at 13,000 xg. The supernatant was then discarded from
each sample and the pelleted cells were resuspended in 100 µL of 2X SDS PAGE loading
buffer containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Glass beads were added
to each resuspended sample before vortexing for one minute. Each sample was boiled at
95 ºC for 5 minutes before storing at -20ºC.
2.18 SDS-PAGE
The IPTG (+) and IPTG (-) samples were analyzed via SDS-PAGE to determine if
SNAP-29 expression had been induced. Firstly, a 12% acrylamide gel was made using a
standardized protocol. Samples were boiled at 94 ºC for 5 minutes before loading onto
the SDS-PAGE gel. Next, 10 µL of each sample was loaded into each well. 1x SDS
running buffer was then added into the running tray. Gel electrophoresis was performed
at 150 V for one hour with varying current. The gel was immersed in a Coomassie
Brilliant Blue R-250 staining solution overnight. The staining solution was then removed,
and the gel was immersed in destaining solution for two hours. Lastly, the gel was
imaged using a gel photoimager and subsequently analyzed.
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Chapter 3: Results
3.1: Amplification of SNAP-29 cDNA
To amplify human SNAP-29 cDNA, a PCR reaction was carried out using the
pMRXIP GFP-SNAP-29 template and primers HXO_E14 and HXO_E15 to insert a 5’
BamHI cut site and a 3’ XhoI cut site into the SNAP-29 cDNA. The PCR product was
purified before electrophoresis. The PCR product showed banding at approximately
0.8 Kb, consistent with the expected size of 777 bp for SNAP-29 (Fig. 6). Subsequent
PCR purification yielded a concentration of 47.5 ng/µL, an A260/280 value of 1.83, and
an A260/230 value of 1.92. Both of the absorbance ratios were nearing 2.0, indicating
adequate purity of the sample. The amplification and purification of SNAP-29 cDNA
using the designed primers generated cDNA which contained restriction sites for BamHI
and XhoI. The insertion of these restriction sites was a crucial step for generating the
recombinant plasmid as it allowed for complementary single-stranded segments to be
generated in both SNAP-29 and pMBP-parallel-1 after double digestion.

Figure 6: SNAP-29 PCR Product
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3.2: Restriction Double Digestion
Following successful PCR amplification and purification of SNAP-29 cDNA,
both SNAP-29 and pMBP-parallel-1 were double digested with BamHI and XhoI. Both
digested products were then subjected to gel electrophoresis and imaged (Fig. 7). The
undigested pMBP-parallel-1 vector shows the typical plasmid banding pattern with three
bands corresponding to circularized (band greater than 10 Kb), nicked (band at 7.5 Kb),
and supercoiled (band at 5.5 Kb) conformations in lane 2. Upon double digestion, pMBPparallel-1 produced a single band at 6.7 Kb, which is consistent with the expected size of
linearized pMBP-parallel-1 in lane 3. Double digested SNAP-29 shows a band at
approximately 0.8 Kb, which is consistent with the expected size of 777 bp for SNAP-29
in lane 4. Because electrophoresis revealed that both pMBP-parallel-1 and SNAP-29
appeared at the expected positions in the gel, these bands were subsequently purified
from the gel. Gel purification yielded a concentration of 27.4 ng/µL with absorbance
ratios of A260/280 = 1.46 and A260/230 = 1.29 for SNAP-29. The absorbance ratios
were well below 2.0, meaning that the DNA sample was contaminated following gel
extraction. Gel purification yielded a concentration of 16.8 ng/µL with absorbance values
of A260/280 = 1.75 and A260/230 = 0.05 for pMBP-parallel-1 (Table 6). The low
A260/230 value indicated that there were residual ethanol and other contaminants that
were not removed during extraction. Because this is a common issue with gel extractions,
these samples were kept and included in a ligation mixture. The ligation reaction utilized
T4 DNA Ligase to insert SNAP-29 into the pMBP-parallel-1 bacterial expression vector.
To control for vector self-ligation, two separate ligation reactions were carried out. In the
experimental condition, a ligation mixture containing T4 DNA Ligase, Ligase Buffer,
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SNAP-29 cDNA, and pMBP-parallel-1 DNA was used. In the vector-only control
condition, the purified SNAP-29 cDNA was omitted. These ligation mixtures were
subsequently used to transform NovaBlue E. coli cells.

Figure 7: Restriction Digestion Products

Table 6: Gel Purification Results
Concentration

A260/280

A260/230

SNAP-29

27.4 ng/μL

1.46

1.29

pMBP-parallel-1

16.8ng/μL

1.75

0.05
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3.3: Transformation of NovaBlue E. coli Cells
Competent NovaBlue E. coli cells were transformed with mixtures from the
ligation reactions. To control for vector self-ligation, two separate transformation
reactions were also carried out. In the experimental condition, the complete ligation
mixture was used to transform NovaBlue cells. In the control condition, the vector only
control ligation mixture was used to transform NovaBlue cells. Colonies that were
formed in the vector only condition correspond to cells that were transformed with
pMBP-parallel-1 that reannealed without inclusion of SNAP-29. This control was
included to assess the number of false positives that were obtained in the experimental
condition. Transformation yielded 136 colonies in the experimental condition and zero
colonies in the vector only condition (Fig. 8). Because no insert was included in the
vector only condition, a circularized plasmid suitable for E. coli transformation was not
formed. The absence of transformants observed in this condition indicated that there was
minimal reannealing of the vector, meaning that any colonies in the experimental
condition likely contained the recombinant plasmid of interest. It was observed that the
colonies appear to be closely localized forming indistinct colonies in some instances. It is
thought that this was due to uneven spreading of the transformation mixtures on the agar
plate while rotating horizontally. To ensure that pure colonies were isolated, two
independent colonies were streaked from the experimental plate onto fresh 100 µg/mL
Ampicillin LB plates. Pure isolated colonies were then subsequently taken from these
plates, inoculated in LB with 100 µg/mL Ampicillin and grown overnight.

27

Figure 8: pMBP-parallel-1-SNAP-29 Transformation Plates LB plate with
100 µg/mL Ampicillin and pMBP-parallel-1 only ligation transformation (Left) and LB
plate with 100 µg/mL Ampicillin and experimental ligation transformation (Right).
3.4: Isolated Plasmid Screening
Plasmids were isolated from two pure independent colonies that grew from
streaked plates. Isolation yielded a DNA concentration of 94.4 ng/µL for isolate #1 and a
DNA concentration of 79.5 ng/µL for isolate #2. Both A260/280 and A260/230
absorbance ratios for each isolate were close to 2.0, indicating high sample purity and the
absence of both organic and inorganic contaminants (Table 7). These isolates were then
double digested with BamHI and XhoI to screen for recombinant plasmids containing
SNAP-29. These digests were subsequently separated on a 0.7% agarose gel and imaged
(Fig. 9). Colonies containing the plasmid of interest should exhibit bands at
approximately 0.8 Kb and 6.7 Kb, corresponding to SNAP-29 and linearized pMBPparallel-1, respectively. Plasmid screening showed that double digested SNAP-29 isolates
#1 and #2 produced bands at approximately 0.8 Kb and 6.7Kb corresponding to SNAP29 and pMBP-parallel-1. Therefore, both isolates were subsequently sent to Eurofins
Genomics for sequencing.
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Table 7: Plasmid Isolation Results

SNAP-29
Isolate #1
SNAP-29
Isolate #2

Concentration

A260/280

A260/230

94.4 ng/μL

1.86

2.33

79.5ng/μL

1.88

2.31

Figure 9: pMBP-parallel-1-SNAP-29 Isolate Screening Lanes 1-4 were represented in
Fig. 7. The SNAP-29 band is indicated by an arrow.
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3.5: Sequencing Confirmation of Isolated Plasmids
After analysis by restriction digestion, the two plasmid isolates shown in Fig. 9
(lanes 5 and 8) were selected for sequencing with a pMBP forward primer. This primer is
complementary to a portion of the MBP sequence within the pMBP-parallel-1 vector
(Table 5). The sequencing results for Isolate #1 showed that 1,143 bp of sequence were
generated and the results for Isolate #2 indicated that 1,122 bp were generated. These
sequences were analyzed using NCBI nBLAST using the expected cDNA obtained from
NCBI for SNAP-29 as the query sequence (Fig. 10). These results showed that both
isolated plasmids contained regions of 100% identity to the query sequence without gaps
or mismatched nucleotides. The start codon is highlighted by a green box while the stop
codon is highlighted by a red box in both Figs. 9A and B.
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A.

B.

Figure 10: pMBP-parallel-1-SNAP-29 Isolate Sequencing Confirmation SNAP-29
Isolate #1 (A) and SNAP-29 Isolate #2 (B) sequencing data with MBP forward
sequencing primer. Both of these figures show 100% similarity, 0 mismatches, and 0
gaps. Green boxes indicate start codons while red boxes indicate stop codons.
The sequences also demonstrated that SNAP-29 was inserted in-frame for both
isolated plasmids. This is indicated by the observation that the methionine codon (ATG)
of the SNAP-29 cDNA is in frame with the TEV site and with the MBP fusion protein
(Fig. 11). These results confirmed that the SNAP-29 cDNA was inserted in frame without
any mutations, so the generated constructs were further used to express SNAP-29 in E.
coli.
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A.

B.

Figure 11: pMBP-parallel-1-SNAP-29 Isolates Confirmed to be In Frame
SNAP-29 Isolate #1 (A) and SNAP-29 Isolate #2 (B) sequencing data with MBP Forward
sequencing primer. The ATG start codon from SNAP-29 is indicated by a green box in
both A and B.
3.6: SNAP-29 Expression
After both pMBP-parallel-1-SNAP-29 constructs had been confirmed, both
constructs were used to transform Rosetta 2 (DE3) E. coli cells. This cell line contains the
pRare plasmid, which codes for tRNAs that are rarely found in bacteria, allowing for
expression of human SNAP-29 without complication due to typical E. coli codon usage
bias (Novy, Drott, Yaeger, & Mierendorf, 2001). This transformation resulted in the
formation of hundreds of colonies for both constructs. Following transformation, a single
colony was streaked out from each plate to ensure that a pure colony was obtained. A
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single colony from each streak plate was inoculated into LB media containing 34 µg/mL
Chloramphenicol and 100 µg/mL Ampicillin and grown in a rotating shaker overnight.
The overnight cultures were then induced with IPTG to express SNAP-29. The cells were
then lysed and their contents were analyzed via SDS-PAGE. The size of each protein was
approximated by comparing the bands in each lane to the bands of known size in the
BroadRange Standard. Because SNAP-29 has a known molecular weight of 29 kDa and
the fusion protein MBP has a known molecular weight of 42.5 kDa, induction was
expected to result in an abundant recombinant polypeptide with a molecular weight of
71.5 kDa. This result is expected as pMBP-parallel-1 codes for the MBP fusion protein
along with the inserted SNAP-29. Using the pMBP-parallel-1 vector allowed for the
expression of MBP-SNAP29. MBP will serve as a tag which may be used for
downstream purification of the protein. The SDS-PAGE results showed that both isolates
produced a heavier band in the IPTG (+) condition at 71.5 kDa than in the IPTG (-)
condition (Figure 12). This finding, along with the consistent expression of actin (band at
42 kDa) and chloramphenicol acetyltransferase (CAT) (band at 26 kDa) across all
conditions indicated that SNAP-29 expression was successfully induced in cells
transformed with both SNAP-29 Isolate #1 and SNAP-29 Isolate #2 recombinant
plasmids. Actin is abundant in the competent Rosetta 2 (DE3) cells and serves as a
marker indicating that cells in all conditions were in the same stage of growth. The CAT
protein is encoded by the pRare plasmid which is found in Rosetta 2 (DE3) cells.
Constant expression of CAT in all conditions further indicates that these cells were all in
the same stage of growth.
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Figure 12: Expression of pMBP-parallel-1-SNAP-29 in Rosetta 2 E. coli Cells
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Chapter 4: Discussion
The SNAP-29 cDNA was successfully amplified by PCR and inserted into the
pMBP-parallel-1 expression vector using restriction digestion and ligation. This construct
was confirmed by sequencing and transformed into Rosetta 2 (DE3) E. coli cells. These
cells were induced with IPTG to express SNAP-29 which was then confirmed by SDSPAGE analysis.
Further efforts within the Xu lab will be aimed at the large-scale IPTG induced
expression of SNAP-29 in Rosetta 2 (DE3) cells that have been transformed with the
recombinant human SNAP-29 cDNA. Following this large-scale expression, the bacterial
cells will be harvested by centrifugation and suspended in a binding buffer. These cells
will then be lysed by a French press technique and centrifuged to remove cellular debris.
Next, these samples will be passed through a filter before application to an amylose resin.
The MBP-SNAP-29 fusion protein will bind tightly to the amylose resin. This will allow
for other proteins that were released from the lysed bacterial cells to be discarded as the
resin is washed with additional binding buffer. An eluting buffer containing maltose will
then be used to elute the MBP-SNAP-29 fusion protein from the amylose resin. Because
MBP has a higher affinity for maltose than amylose, elution will occur readily. The
purified SNAP-29 will then be treated with TEV protease to cleave the MBP fusion tag
from SNAP-29. Finally, the purified and processed SNAP-29 protein will be used in
experiments to decipher its interactions with ORF33/38.
To dissect the functional interactions between SNAP-29 and ORF33/38, lipid
mixing assays will be utilized. The purified SNAP-29 protein will be incorporated into
artificial autophagosomes along with Qa-SNARE STX-17. These artificial
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autophagosomes will then be mixed with artificial lysosomes containing the SNAP-29
cognate SNARE partner, VAMP-8. The autophagosome will contain quenched florescent
lipids that will fluoresce upon mixing with lipids from the artificial lysosome. Measuring
the degree of florescence over a one-hour period will, thus, measure the degree of fusion
that occurs between the two artificial membranes. The KSHV ORF33/38 proteins will
also be included in the assays in a range of concentrations to assay how this protein
complex affects membrane fusion.
To delineate the structural elements in SNAP-29 that are required for interaction
with ORF33/38, a mutational analysis approach will be employed. In these investigations,
the wild-type SNAP-29 protein that was expressed in this project will be used in control
assays to examine how wild-type SNAP-29 and VAMP-8 membranes are able to fuse in
the presence of ORF33/38. Site-directed mutagenesis will then be utilized in order to
introduce single amino acid mutations within key SNAP-29 domains in the recombinant
plasmid that was produced as a part of this project. Lipid mixing assays will be carried
out as described, but mutant SNAP-29 proteins will be utilized. For one phase of this
experiment, the SNAP-29 residue Q161 will be replaced by an alanine residue by sitedirected mutagenesis. Lipid mixing assays will then be employed to determine if
ORF33/38 interacts with SNAP-29 in the same manner as the EV-D68 C3 protein.
Further mutants will also be generated by altering the amino acid sequence of SNAP-29’s
Qa-SNARE domain (75-115) and Qb-SNARE domain (213-258). These mutants will be
expressed and utilized in lipid-mixing assays to test ORF33/38 interactions with these
domains. The results gleaned from these mutational lipid-mixing assays are anticipated to
reveal amino acid substitutions which increase fusion of mutant SNAP-29/wild-type
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STX-17 membranes with VAMP-8 membranes in the presence of ORF33/38. Thus, these
substituted amino acids could represent sites which could be modulated by drug binding.
Identifying the specific residues involved in the SNAP-29 and ORF33/38
interaction would create a foundation for a novel mechanism by which KSHV infection
could be combatted. Pharmaceutical agents could be designed to modulate these amino
acids to fortify autophagosome-lysosome binding in mast cells. This approach would
allow mast cells to better clear KSHV and would render the cells unable to serve as
reservoirs of infection. These drugs could effectively inhibit the long-term perpetuation
of KSHV infection and resultant tumor maturation within Kaposi’s Sarcoma. This
approach, combined with conventional therapies, holds promise to provide a more
effective means of treating Kaposi’s Sarcoma.
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